IPCEI — Important Projects of Common European Interest — is the most powerful funding mechanism in the European industrial policy toolkit. By allowing EU member states to exceed normal State Aid limits for cross-border R&D projects, IPCEI enables the kind of large-scale, coordinated investment in strategic technologies that markets cannot generate alone. France is the most active IPCEI participant in Europe, with commitments across five approved IPCEI projects totaling over €3 billion in French state support — a track record that reflects both France’s strategic ambition and its political capacity to push these complex, multi-year European negotiations forward.

What Makes IPCEI Different

Standard EU State Aid rules impose strict limits on what governments can pay companies for research and industrial investment. These limits prevent unfair competitive advantages — but they also prevent the kind of large-scale, coordinated public investment that genuinely strategic technologies require. The US CHIPS Act’s $52 billion direct subsidy to semiconductor manufacturers would be illegal under standard EU State Aid rules.

IPCEI is the EU’s answer to this constraint. Under Article 107(3)(b) of the Treaty on the Functioning of the EU, member states can approve aid for “important projects of common European interest” that transcend normal State Aid limits. To qualify as an IPCEI:

1. The project must involve at least four EU member states
2. It must address a clear market failure that private investment alone cannot resolve
3. It must cover the value chain from research to first commercial application (pre-commercial phase only — pure production subsidies do not qualify)
4. The projects in each member state must be linked across borders (knowledge sharing, supply chain integration, or complementary technology development)
5. Benefits must spill over to the broader European economy, not just the direct beneficiaries

These requirements make IPCEI projects genuinely complex to design and approve — the hydrogen IPCEI took three years from concept to European Commission approval. But they also create the most durable form of European industrial policy: coordinated across multiple countries, legally cleared at the highest level, and structurally integrated into European value chains.

France’s IPCEI Track Record: Five Programs

IPCEI Batteries — France 2030 Support: €1.3 billion

The first IPCEI approved for batteries (2021) was the mechanism through which France backed ACC — the Automotive Cells Company joint venture between Stellantis, TotalEnergies, and Mercedes-Benz. ACC received €810 million in French state support through IPCEI Batteries, making it the single largest France 2030 grant to any individual project.

France’s IPCEI Batteries participation extends beyond ACC to include research partners at CEA, the University of Amiens (sodium-ion chemistry), and several battery materials companies. The cross-border dimension includes coordination with Germany (BMW, Volkswagen battery research), Belgium (BASF), and Poland (ElevenEs, a CNRS spin-off that relocated to Poznan).

Total French IPCEI Batteries commitment: approximately €1.3 billion Key French beneficiaries: ACC (€810M), CEA research (€120M), Tiamat Energy (€40M), materials suppliers (€330M)

IPCEI Hydrogen — France 2030 Support: €750 million

Approved by the European Commission in 2022, IPCEI Hydrogen involves 35 companies across 15 EU member states. France’s participation is the most geographically concentrated — centered on the Normandie and Hauts-de-France hydrogen valleys — and technically diverse, covering all three principal electrolyzer technologies (PEM, alkaline, SOEC).

French IPCEI Hydrogen participants:

The hydrogen IPCEI is also the most challenging in execution: of the seven French beneficiaries, deployment timelines have slipped by 18 to 24 months due to technology readiness and electricity cost constraints. Lhyfe’s Sealhyfe offshore platform is operational. Genvia’s Béziers pilot is under construction. The larger production facilities from Air Liquide and others remain in pre-commercial development.

IPCEI Microelectronics Phase 2 — France 2030 Support: €1.0 billion

The second Microelectronics IPCEI (approved 2022) involves 68 direct participants across 14 member states — the largest IPCEI by company count. France’s participation is anchored on the Crolles semiconductor cluster:

• STMicroelectronics: Advanced process R&D and manufacturing scale-up (dominant beneficiary)
• Soitec: SOI wafer technology for next-generation nodes
• Lynred (Grenoble): Infrared sensor arrays — a specialized imaging technology where France holds global leadership
• Tronics Microsystems (Grenoble): MEMS inertial sensors
• CEA-LETI: Research contributions feeding into manufacturing development

The French IPCEI Microelectronics support (approximately €1 billion) complements the national Nano 2030 investment and the bilateral Aide aux Projets Structurants for the STMicro-GlobalFoundries joint fab expansion.

IPCEI Cloud Infrastructure and Services — France 2030 Support: €450 million

Approved 2021, IPCEI Cloud is the most controversial of the five French IPCEI participations. The cloud sovereignty argument — that European data should be processed on European infrastructure subject to European law — is politically compelling but economically complex, given the scale advantages held by AWS, Azure, and Google Cloud.

France’s IPCEI Cloud participation focuses on the European hyperscaler tier:

• OVHcloud (Roubaix): Europe’s largest cloud provider by physical infrastructure. OVHcloud’s IPCEI support funds next-generation sovereign cloud architecture, hybrid cloud federation standards, and the technical infrastructure for SecNumCloud-qualified services. Approximately €200 million.
• Scaleway (Iliad Group, Paris): AI-optimized GPU cloud and sovereign infrastructure. France 2030 supports Scaleway’s GPU cluster expansion and its development of open sovereign cloud APIs. Approximately €150 million.
• Outscale (Dassault Systèmes): Industrial and government cloud platform. Approximately €100 million.

The cross-border dimension of IPCEI Cloud involves technical interoperability standards development — enabling data to move between national clouds in Germany, France, and Spain while maintaining legal jurisdiction certainty.

IPCEI Health — France 2030 Support: €200 million

The most recent IPCEI in France’s portfolio, IPCEI Health focuses on bioproduction of innovative medicines — biologics, ATMPs (Advanced Therapy Medicinal Products), and next-generation vaccine platforms. France’s participation is dominated by Sanofi’s mRNA manufacturing investments.

• Sanofi (Vitry-sur-Seine): mRNA drug substance manufacturing scale-up, integrated with the broader ProFIL bioproduction strategy
• Yposkesi (Évry-Courcouronnes): Cell and gene therapy manufacturing platform, co-funded by Genethon and France 2030
• Research contribution through INSERM and INRAE for bioproduction process technology

IPCEI Health cross-border coordination involves Germany (BioNTech, CureVac), Belgium (UCB), and Sweden (AstraZeneca Sweden operations) — creating a complementary European bioproduction network rather than a single-country supply chain.

IPCEI vs. National France 2030 Competitions: Which Is Better?

The IPCEI route is superior for large projects with genuine cross-border value chains and long pre-commercial development phases. The advantages:

• Higher State Aid ceiling: No strict percentage cap on aid intensity (versus 45-50% for large companies under standard rules)
• Multi-year commitment: IPCEI approval locks in state support commitments for 5 to 10 year horizons, providing planning certainty that annual budget processes cannot
• European legitimacy: EC approval provides legal certainty against State Aid challenge — critical for projects that compete internationally
• Network effects: IPCEI participation connects French companies with European counterparts, supply chain partners, and co-investors

The disadvantages:

• Timeline: 2 to 4 years from concept to European Commission approval
• Administrative burden: IPCEI application and compliance reporting is substantially heavier than national competition processes
• Cross-border requirements: Companies must genuinely collaborate across borders, not simply declare nominal partnerships

For projects below €100 million in public support, national competitions (I-Démo, Aide aux Projets Structurants) are faster and simpler. For transformative projects requiring €200 million or more in public support and genuine pan-European supply chain integration, IPCEI is the appropriate mechanism.

France’s IPCEI Leadership in European Context

France has participated in every major IPCEI approved since 2014. No other member state has a comparable record:

• Germany participates in more IPCEIs by total number, but with smaller per-project commitments (German federal structure distributes investment across Länder)
• The Netherlands leads in per-capita IPCEI investment, reflecting its semiconductor cluster (ASML, NXP, Philips Healthcare)
• Italy and Spain have increased IPCEI participation under their respective national recovery plans, but remain secondary players

France’s IPCEI prominence reflects deliberate strategy: French officials at SGPI and the Ministry of Economy have invested in building IPCEI negotiation expertise, maintaining permanent working relationships with DG Competition (the European Commission’s State Aid directorate), and leading the political coalitions within the European Council that approve IPCEI frameworks.

This institutional knowledge compounds: France’s speed and effectiveness in securing new IPCEI approvals has increased with each successive program, creating a durable competitive advantage in accessing European co-funding for industrial sovereignty investments.